Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study

@article{Holz2014SignificantRI,
  title={Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study},
  author={Caterina Holz and Andreas Busjahn and Heidrun Mehling and S. K. Das Arya and Mewes Boettner and Hajar Habibi and Christine Lang},
  journal={Probiotics and Antimicrobial Proteins},
  year={2014},
  volume={7},
  pages={91 - 100}
}
Abstract Reducing the amount of Helicobacter pylori in the stomach by selective bacterial–bacterial cell interaction was sought as an effective and novel method for combating the stomach pathogen. Lactobacillus reuteri DSM17648 was identified as a highly specific binding antagonist to H. pylori among more than 700 wild-type strains of Lactobacillus species. Applying a stringent screening procedure, the strain DSM17648 was identified as selective binder to H. pylori cells under in vivo gastric… Expand
Non-Viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a New Approach to Helicobacter pylori Control in Humans
TLDR
The potential of Pylopass™ as a novel way to reduce the load of H. pylori is confirmed and spray-drying cells of L. reuteri DSMZ17648 have been used in a human study and results are in line with the first study results, supplementing with freeze-dried material. Expand
The effect of Lactobacillus reuteri supplementation in Helicobacter pylori infection: a placebo-controlled, single-blind study
TLDR
The results demonstrated that L. reuteri DSM17648 has the potential to suppress H. pylori infection, and may lead to an improvement of H.pylori-associated gastro intestinal symptoms. Expand
Anti-Helicobacter pylori activity of non-living, heat-killed form of lactobacilli including Lactobacillus johnsonii No.1088
TLDR
It is found that a non-living heat-killed form of Lactobacillus johnsonii No.1088 (HK-LJ88) and also that of some other lactobacilli inhibited the growth of H. pylori in vitro. Expand
Значение Lactobacillus reuteri DSMZ17648 в эрадикационной терапии инфекции Helicobacter pylori (Обзор литературы и резолюция Экспертного совета, 28 февраля 2018 г.)
TLDR
It was revealed that lyophilizate of this strain (PylopassTM) blocks adhesion of H. pylori to epithelial cells as well and the value of monotherapy by this metabiotic at chronic H.pyloriassociated gastritis is a subject of further studies. Expand
Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections
TLDR
Results showed that in addition to decrease gastrointestinal symptoms, probiotics can reduce the side effects of antibiotics by altering the intestinal microbiome, and antagonist activities of probiotics are H. pylori strain-specific. Expand
Limosilactobacillus reuteri Strains as Adjuvants in the Management of Helicobacter pylori Infection
TLDR
As an adjuvant of standard regimens with antibiotics and pump inhibitors, L. reuteri can be used not only to improve cure rates, but especially to decrease gastrointestinal symptoms, which are a common cause of lack of compliance and interruption of therapy, leading to new antibiotic resistance. Expand
Are probiotics useful for therapy of Helicobacter pylori diseases?
TLDR
Probiotics are a useful tool for improving the rate of eradication and reduction of side effects of H. pylori infections and some probiotic bacterial species could be useful with drug therapy. Expand
Probiotic and technological properties of Lactobacillus spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis
TLDR
This work characterizes a set of lactobacilli strains isolated from the stomach of healthy humans that might serve as probiotic cultures, and deems two L. reuteri strains as the most appropriate candidates to be used as potential probiotics against microbial gastric disorders. Expand
Probiotic therapy in Helicobacter pylori infection: a potential strategy against a serious pathogen?
TLDR
This review is focused on probiotic’s antagonism against H. pylori summarizing their three main potential aspects: their efficiency as an alternative to H.pylori eradication treatment, their effectiveness as an adjunct toH. Expand
H. pylori and its modulation of gastrointestinal microbiota
TLDR
The development of new nucleotide sequencing techniques and new biocomputational tools has opened the field for studying the diversity and complexity of the microbiome in the gastrointestinal tract independently of cultural methods to better characterize further gastric bacteria. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 46 REFERENCES
Non-Viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a New Approach to Helicobacter pylori Control in Humans
TLDR
The potential of Pylopass™ as a novel way to reduce the load of H. pylori is confirmed and spray-drying cells of L. reuteri DSMZ17648 have been used in a human study and results are in line with the first study results, supplementing with freeze-dried material. Expand
Lactobacillus reuteri in the treatment of Helicobacter pylori infection
TLDR
L. reuteri may have a potential role in H. pylori eradication therapy if the cure rate can be improved by changes in dose, dosing interval, or duration of therapy. Expand
In vitro screening of lactobacilli with antagonistic activity against Helicobacter pylori from traditionally fermented foods.
TLDR
The results indicate that 2 Lactobacillus strains showed potential anti-H. Expand
Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: a double-blind placebo-controlled randomized clinical trial
TLDR
Test whether the addition of Lactobacillus reuteri to the standard triple therapy improves the eradication rates as well as the clinical and pathological aspects in H. pylori infection when compared with placebo-supplemented triple therapy found it to be effective. Expand
Bacterial Load and Degree of Gastric Mucosal Inflammation in Helicobacter pylori Infection
TLDR
Overall, high bacterial loads are associated with increased acute mucosal damage and long-term changes in the gastric mucosa and Treatments suppressing the density and virulence of H. pylori could become strategies to prevent H.pylori-associated disease in the future. Expand
Eradication of Helicobacter pylori: Past, present and future.
TLDR
The purpose of this review is to provide an overview about the current therapy and its limitations, while highlighting the possibility of using micro- and nanotechnology to develop gastric drug delivery systems, overcoming these difficulties in the future. Expand
Diagnosis of Helicobacter pylori Infection
TLDR
The breakthrough this year was the direct in vivo observation of H. pylori during endoscopy, and the usefulness of some serologic markers as indicators of the gastric mucosa status was explored. Expand
Successful culture techniques for Helicobacter species: general culture techniques for Helicobacter pylori.
TLDR
This chapter describes successful techniques for culturing H. pylori on selective horse blood agar media and in Brucella broth liquid media and the specific growth requirements of other Helicobacter species are noted. Expand
Specific Lactobacillus/Mutans Streptococcus Co-aggregation
Selective interaction of mutans streptococci with benign bacteria could present an opportunity for their removal from the mouth without disruption of other oral flora. This study was conducted toExpand
Eradication of Helicobacter pylori infection.
  • R. Hunt
  • Medicine
  • The American journal of medicine
  • 1996
TLDR
It is reasonable to consider all patients with confirmed duodenal or gastric ulcer for eradication of H. pylori, and no patient should be considered for elective surgery without first being offered eradication therapy. Expand
...
1
2
3
4
5
...